Organization | Yiling Pharmaceutical Inc.

Yiling Pharmaceutical Inc. Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Shijiazhuang China (1992)

Status: No NME R&D (1992)

Organization Overview

First Clinical Trial

2014

NCT02035644

First Marketed Drug

2007

amlodipine (norvasc)

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

BEIJING YILING | Boao Yiling Life Care Center | Conjupro Biotherapeutics | Conjupro Biotherapeutics, Inc. | Conupro Biotehrapeutics, and CSPC | CSPC Ouyi Pharmaceutical Co., Ltd. | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Shijiazhuang Yiling Pharmaceutical company, LTD | YILING | Yiling Pharmaceutical | Yiling Pharmaceutical Inc. | YILING PHARM LTD

Active Ingredients

Marketed Drugs (15)

aciclovir (zovirax) (2018)

amlodipine (norvasc) (2007)

anastrozole (arimidex) (2018)

buspirone (buspar) (2015)

celecoxib (celebrex) (2020)

ciprofloxacin (cipro) (2018)

felodipine (plendil) (2018)

lamotrigine (lamictal) (2021)

letrozole (femara) (2018)

lisinopril (zestril) (2020)

memantine (namenda) (2020)

paroxetine (paxil) (2021)

pregabalin (lyrica) (2019)

sildenafil (viagra) (2012)

valaciclovir (Valtrex) (2020)

Drugs in Phase 4 Trials (7)

alendronic acid (fosamax) (1 trial)

alosetron (lotronex) (1 trial)

carboplatin (paraplatin) (6 trials)

jinlida (1 trial)

paclitaxel (taxol) (18 trials)

sintilimab (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 3 Trials (15)

capecitabine (xeloda) (3 trials)

cyclophosphamide (cytoxan) (6 trials)

Dexketoprofen (4 trials)

docetaxel (taxotere) (4 trials)

doxorubicin (Doxil) (6 trials)

gimeracil (1 trial)

oteracil (1 trial)

oxaliplatin (eloxatin) (4 trials)

pertuzumab (perjeta) (2 trials)

syhx2011 (2 trials)

tegafur (2 trials)

trastuzumab (herceptin) (3 trials)

tromethamine (tham) (4 trials)

xy0206 (3 trials)

Drugs in Phase 2 Trials (23)

acetylsalicylic acid (aspirin) (1 trial)

butylphthalide (1 trial)

chidamide (1 trial)

cisplatin (platinol) (4 trials)

cpo107 (1 trial)

dexamethasone (1 trial)

duvelisib (copiktra) (1 trial)

epirubicin (ellence) (4 trials)

fluorouracil (efudex) (3 trials)

gemcitabine (gemzar) (5 trials)

irinotecan (Camptosar) (6 trials)

kt07 (2 trials)

lenalidomide (revlimid) (1 trial)

leucovorin (3 trials)

mitoxantrone (novantrone) (9 trials)

rituximab (rituxan) (3 trials)

sg001 (1 trial)

syhx1901 (1 trial)

temozolomide (temodar) (1 trial)

triprizumab (1 trial)

venetoclax (venclexta) (1 trial)

vincristine (oncovin) (3 trials)

xy03-ea (1 trial)

Drugs in Phase 1 Trials (13)

amlodipine (norvasc) (1 trial)

cpo102 (1 trial)

cpo301 (1 trial)

etoposide (vepesid) (1 trial)

ha115 (1 trial)

lbs-008 (1 trial)

levamlodipine (Conjupri) (1 trial)

phentermine (wyamine) (3 trials)

prednisone (meticorten) (1 trial)

syh2043 (1 trial)

syhx 1901 (1 trial)

syhx2005 (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Other Trials (2)

pirarubicin (1 trial)

prednisolone (hydeltra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 3)

Asthma (Phase 1)

Biliary Tract Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Cognitive Dysfunction (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Dyslipidemias (Phase 4)

Epilepsy (Phase 2)

Hypertension (Phase 1)

Influenza, Human (Phase 2)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Parkinson Disease (Phase 1)

Sclerosis (Phase 2)

Stomach Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Tuberous Sclerosis (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 65
# of Trial APIs: 60